Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075473 | 0.78 | TNKS2 (0.55) | GAAMAPTMEN1KMT2ATNKS2 | |
| SCHEMBL17376745 | 0.73 | CREBBP (0.42) | CREBBPBRPF1GAAMAPTMEN1 | |
| SCHEMBL6831860 | 0.73 | HTR2A (0.35) | MAPTMEN1KMT2AIDO1KDM1A | |
| SCHEMBL31145667 | 0.71 | MEN1 (0.40) | GAAMAPTMEN1KMT2AALOX15 | |
| SCHEMBL3468367 | 0.71 | MEN1 (0.40) | GAAMAPTMEN1KMT2AALOX15 | |
| SCHEMBL6834602 | 0.69 | KDM1A (0.35) | CREBBPBRPF1GAAMAPTMEN1 | |
| SCHEMBL23260314 | 0.69 | — | — | |
| SCHEMBL12379793 | 0.69 | HTR2A (0.41) | CREBBPBRPF1GAAMAPTMEN1 | |
| SCHEMBL8279432 | 0.69 | CREBBP (0.50) | CREBBPBRPF1GAAMAPTMEN1 | |
| SCHEMBL12841651 | 0.69 | CREBBP (0.39) | CREBBPBRPF1GAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-22 | — | — | US | claimed |
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-22 | — | — | US | disclosed |
| CN-1100535-C | Pharmaceutical agents for treatment of emesis | PFIZER (US) | 2003-02-05 | — | — | CN | disclosed |
| CN-1132072-A | NK-1 receptor antagonists for the treatment of nerve injury and stroke | PFIZER (US) | 1996-10-02 | — | — | CN | disclosed |
| CN-1121806-A | Pharmaceutical agents for treatment of emesis | PFIZER (US) | 1996-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | TNNI3, MYLK2, FABP3 | CREBBP 1092/4885BRPF1 1959/4885GAA 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.